September 4, 2001Circulation
Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries
Why the study?
Does BQ-123 infusion improve coronary artery dilation in patients with CAD compared to those with normal coronary arteries?
Population
16 patients, comprising 8 with coronary artery disease with >50% stenosis in a major coronary artery and 8…
Comparison
BQ-123 (ET receptor antagonist) infused into a… vs Noninfused coronary artery and intracoronary…
Design
Other
Follow-up
60 minutes
Authors
Discussion
Loading...
Member takes
Implication
ET-1 antagonism may relieve stenotic tone in CAD; leaves open whether it reduces ischemia or events.
Structured PICO
Does BQ-123 infusion improve coronary artery dilation in patients with CAD compared to those with normal coronary arteries?
P
Population
16 patients, comprising 8 with coronary artery disease (CAD) with >50% stenosis in a major coronary artery and 8 with angiographically smooth coronary arteries (normal).
I
Intervention
BQ-123 (ET(A) receptor antagonist) infused into a major coronary artery at 40 nmol/min for 60 minutes.
C
Comparator
Noninfused coronary artery (internal control) and intracoronary nitroglycerin (200 microgram).
O
Outcome
Dilation of the infused artery measured by quantitative angiography at 60 minutes.surrogate
Endothelin-1 contributes significantly to resting tone in atherosclerotic coronary arteries, suggesting ET-1 inhibitors could reduce myocardial ischemia by relieving constriction at stenoses.
Cite This Study
Kinlay et al. (2001) studied this question.